Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease

Item Type:	Article
Title:	Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease
Creators Name:	Hockly, E. and Tse, J. and Barker, A.L. and Moolman, D.L. and Beunard, J.L. and Revington, A.P. and Holt, K. and Sunshine, S. and Moffitt, H. and Sathasivam, K. and Woodman, B. and Wanker, E.E. and Lowden, P.A. and Bates, G.P.
Abstract:	Huntington's disease (HD) is an inherited progressive neurological disorder for which there is no effective therapy. It is caused by a CAG/polyglutamine repeat expansion that leads to abnormal protein aggregation and deposition in the brain. Several compounds have been shown to disrupt the aggregation process in vitro, including a number of benzothiazoles. To further explore the therapeutic potential of the benzothiazole aggregation inhibitors, we assessed PGL-135 and riluzole in hippocampal slice cultures derived from the R6/2 mouse, confirming their ability to inhibit aggregation with an EC50 of 40 μM in this system. Preliminary pharmacological work showed that PGL-135 was metabolically unstable, and therefore, we conducted a preclinical trial in the R6/2 mouse with riluzole. At the maximum tolerated dose, we achieved steady-state riluzole levels of 100 μM in brain. However, this was insufficient to inhibit aggregation in vivo and we found no improvement in the disease phenotype.
Keywords:	Aggregation Inhibitor, Benzothiazole, Huntingtons Disease, Neurodegeneration, Polyglutamine, R6/2, Riluzole, Animals, Mice
Source:	Neurobiology of Disease
ISSN:	0969-9961
Publisher:	Elsevier
Volume:	21
Number:	1
Page Range:	228-236
Date:	January 2006
Official Publication:	https://doi.org/10.1016/j.nbd.2005.07.007
PubMed:	View item in PubMed

Repository Staff Only: item control page